SCHEMBL6712596

SCHEMBL6712596

CC(C)(C)C1CCC(=CC(=O)O)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.37
CES2 O00748 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 4/20 0.35
EPHX1 P07099 1/20 0.34
MAPT P10636 5/20 0.34
ALDH1A1 P00352 3/20 0.34
LMNA P02545 3/20 0.34
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
ANO1 Q5XXA6 1/20 0.33
LIPA P38571 1/20 0.33
USP2 O75604 1/20 0.32
RAB9A P51151 1/20 0.32
CYP2D6 P10635 1/20 0.32
KCNH2 Q12809 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6274804 0.93 GLA (0.33) GLACES2SMN1; SMN2MEN1KMT2A
SCHEMBL3836552 0.80 HK2 (0.44) RAB9ATSHR
SCHEMBL7776727 0.79 SMN1; SMN2 (0.36) GLASMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL7310223 0.77 TSHR (0.34) ALDH1A1USP2GAATSHR
SCHEMBL28122937 0.74 SMN1; SMN2 (0.33) GLASMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL3841912 0.72 TSHR (0.34) TSHR
SCHEMBL21734166 0.72 TSHR (0.34) TSHR
SCHEMBL12983433 0.72 ITGB3 (0.40) LMNARAB9ACYP2D6TSHR
SCHEMBL1931711 0.72
Bicarbonate SCHEMBL5597464 0.69 EPHX1 (0.55) GLACES2SMN1; SMN2KDM4EEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040209858-A1 Cycloalkylamides and their therapeutic applications ABBOTT LABORATORIES 2004-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209858-A1 Cycloalkylamides and their therapeutic applications GAP43, SCN1B, GRIN2B GLA 1085/4885CES2 777/4885SMN1; SMN2 473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.